Trial Profile
A Dose Escalation Study of NK-92 Cell Infusions in Patients With Hematological Malignancies in Relapse After Autologous Stem Cell Transplantation.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 02 Aug 2017
Price :
$35
*
At a glance
- Drugs CST 101 (Primary)
- Indications Haematological malignancies; Hodgkin's disease; Leukaemia; Lymphoma; Myeloma
- Focus Adverse reactions
- 31 Jul 2017 Results from this trial have been published in the journal Oncotarget, according to NantKwest media release.
- 31 Jul 2017 Final results published in NantKwest media release.
- 21 Jun 2016 Status changed from recruiting to completed.